Method of inhibiting prostate cancer cell proliferation

Details Method of inhibiting prostate cancer cell proliferation Method of inhibiting prostate cancer cell proliferation

2011-04-05

2011-04-05

Rawlings, Stephen L (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S317000, C530S330000, C530S350000, C514S002600, C514S017400

Reexamination Certificate

active

07919458

ABSTRACT:
The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA2inhibitor. In one embodiment the PLA2inhibitor is a conformationally constrained molecule derived from a peptide consisting essentially of amino acid residues 70-74 of a human sPLA2-IIA protein, or the equivalent residues in other sPLA2proteins.

REFERENCES:
patent: 5656602 (1997-08-01), Tseng et al.
patent: 5942402 (1999-08-01), Schmidt et al.
patent: 1 300 159 (2003-04-01), None
patent: 1 329 511 (2003-07-01), None
patent: WO 96/40657 (1996-12-01), None
patent: WO 98/05349 (1998-02-01), None
patent: WO 98/05349 (1998-02-01), None
patent: WO 02/24923 (2002-03-01), None
patent: WO 02/38575 (2002-05-01), None
patent: WO 03/014082 (2003-02-01), None
Markova et al. (Oncogene. Sep. 22, 2005; 24 (42): 6450-6458).
Murkami et al. (J. Biochem. Mar. 2002; 131 (3): 285-292).
Masuda et al. (Biochim. Biophys. Acta. 2005; 1736: 200-210).
Suzuki et al. (J. Biol. Chem. Feb. 25, 2000; 275 (8): 5785-5793).
Menschikowski et al. (Neoplasia. Mar. 2008; 10 (3): 279-286).
Finjeman et al. (Front. Biosci. May 1, 2008; 13: 4144-4174).
Rose et al. (Prostate. 1991; 18 (3): 243-254).
Jaulmes et al. (Arterioscler. Thromb. Vasc. Biol. Jun. 2005; 25 (6): 1161-1167).
Kelland et al. (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Tseng et al. (J. Biol. Chem. Sep. 27, 1996; 271 (39): 23992-23998).
Gura (Science. 1997; 278: 1041-1042).
Dennis (Nature. Aug. 7, 2006; 442: 739-741).
Schuh (Toxicologic Pathology. 2004; 32 (Suppl. 1): 53-66).
Bibby (Eur. J. Cancer. Apr. 2004; 40 (6): 852-857).
Peterson et al. (Eur. J. Cancer. 2004; 40: 837-844).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Sved et al. (Cancer Res. Oct. 1, 2004; 64: 6934-6940).
Thwin et al. (J. Med. Chem. 2007; 50: 5938-5950).
Church et al. (J. Biol. Chem. Aug. 31, 2001; 276 (35): 33156-33164).
Liu et al. (J. Urol. Sep. 2000; 164: 820-825).
Kelavkar et al. (Carcinogenesis. Nov. 2001; 22 (11): 1765-1773).
Patel et al. (Clin. Cancer Res. Dec. 15, 2008; 14 (24): 8070-8079).
Dong et al. (Cancer Lett. Aug. 18, 2006; 240 (1): 9-16).
Scott et al. (Biochimie. Jun. 2010; 92 (6): 601-610).
Attiga, F.A., et al; “Inhibitors of Prostaglandin Synthesis Inhibit Human Prostate Tumour Cell Invasiveness and Reduce the Release of Matrix Metalloproteinases”;Cancer Research, vol. 60, pp. 4629-4637 (2000).
De Souza, P.L., et al; “Enhancement of Paclitaxel Activity Against Hormone-Refractory Prostate Cancer Cells in Vitro and in Vivo by Quinacrine”;British Journal of Cancer; vol. 75(11); pp. 1593-1600 (1997).
Jiang, J., et al; “Expression of Group IIA Secretory Phospholipase A2 Is Elevated in Prostatic Intraepithelial Neoplasia and Adenocarcinoma”;American Journal of Pathology; vol. 160, No. 2; pp. 667-670; (2002).
Graff, J.R., et al; “Expression of Group IIA Secretory Phospholipase A2 Increases with Prostate Tumor Grade”;Clinical Cancer Research; vol. 7; pp. 3857-3861 (2001).
Lehr, M.; “Phospholipase A2Inhibitors in Inflammation”;Expert Opinion; Ashley Publications; pp. 1123-1136 (2001).
Scott, K.F., et al; “Secreted Phospholipase A2Enzymes as Therapeutic Targets”;Expert Opinion; Ashley Publications; pp. 1-14 (2003).
Ono, T., et al; “Characterization of a novel inhibitor of cytosolic phospholipase A2α, pyrrophenone”;Biochem, J.; vol. 363; pp. 727-735 (2002) (XP-002532197).
Sved, P., et al; “Oncogenic Action of Secreted Phospholipase A2in Prostate Cancer”;Cancer Research; vol. 64; pp. 6934-6940 (2004) (XP-002532198).

Affiliated with

Also associated with

Rating

Method of inhibiting prostate cancer cell proliferation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of inhibiting prostate cancer cell proliferation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting prostate cancer cell proliferation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2647584